Akari Therapeutics announces 1-for-40 reverse split to address Nasdaq delisting risk

Filed March 17, 2026 · Period ending March 17, 2026 · ~1 min read

Key Changes

• high

  Company implementing 1-for-40 reverse split of ADSs effective March 31, reducing outstanding shares by 97.5% to boost per-share price and meet Nasdaq's minimum bid requirement.

  Item 8.01 view on EDGAR →
• high

  Akari explicitly warns it cannot guarantee the reverse split will achieve or maintain Nasdaq compliance, indicating significant delisting risk remains even after the split.

  Item 8.01 view on EDGAR →
• medium

  The reverse split changes ADS ratio from 1:2,000 to 1:80,000 ordinary shares but does not affect underlying ordinary shares or total company ownership structure.

  Item 8.01 view on EDGAR →